Dror Ortho-Design Receives 510(k) FDA Clearance for Next-Generation Smile Correction Solution

FDA clearance paves the way for U.S. commercial launch of innovative alternative to traditional alignersJERUSALEM, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Dror Ortho-Design, Inc. ("Dror" or the "Company") ...
European Medical Journal

Gum Disease and Mild Cognitive Impairment

Severe periodontitis has been linked to systemic inflammatory burden, and a new cross-sectional study suggests it may also track with subtle cognitive changes in midlife. Investigators evaluated 102 ...
jmg.bmj

Under-recognised neurocognitive deficits in adults and adolescents with tuberous sclerosis complex

Background Tuberous sclerosis complex (TSC) is a genetic disease characterised by the growth of benign tumours. The Tuberous sclerosis Associated Neuropsychiatric Disorders (TAND) Checklist is used to ...
Multiple Sclerosis News Today

Coping with cognitive changes in SPMS

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google When you have secondary progressive multiple sclerosis (SPMS), ...
Neurology Advisor

Gene Therapy Slows Huntington Disease Progression in Pivotal Trial

uniQure is targeting a BLA submission in the first quarter of 2026. Topline data were announced from a pivotal phase 1/2 study evaluating AMT-130 in patients with Huntington disease (HD). AMT-130 is a ...
GEN

StockWatch: uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s Data

The dazzling 36-month clinical data announced by uniQure (NASDAQ: QURE) showing a significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate ...
Seeking Alpha

uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond

The last time I wrote an article on uniQure N.V. (QURE), it was in a Seeking Alpha article entitled "uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting." With respect to that article, ...
Seeking Alpha

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external ...
GEN

Gene Therapy Significantly Slows Huntington Disease Progression

uniQure reported positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington’s disease. The study met its prespecified primary endpoint, with high-dose AMT-130 ...
eLife

In vivo mapping of striatal neurodegeneration in Huntington’s disease with Soma and Neurite Density Imaging

This important manuscript presents a novel application of the SANDI (Soma and Neurite Density Imaging) model to study microstructural alterations in the basal ganglia of individuals with Huntington's ...